Novartis R&D Day

Our drug discovery and development engine has the scope and scale to innovate the next generation of medicines. We’re harnessing powerful and advanced therapy platforms to take on big scientific challenges and find opportunities to develop breakthrough medicines for patients.

Learn more in our media release.

…
/by

Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day

  • Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms
  • 60 projects in Phase 2 pipeline with 10+ advancing into Phase 3 or pivotal trials each year in 2020 and 2021; over 90% projected to be first-in-class or first-in-indication
  • Emerging assets address areas of high unmet need including iscalimab in transplant and Sjögren’s syndrome, LNP023 in renal diseases and PNH, MBG453 in MDS, and TQJ230 in cardiovascular risk reduction
  • …
/by

Novartis tender offer for The Medicines Company commences

Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ: MDCO) for a price of USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding (the “Offer”).  The Offer is being made upon the terms and subject to the conditions set forth in the Offer to …

/by

Amazon Web Services (AWS) Announces Strategic Collaboration with Novartis to Accelerate Digital Transformation of its Business Operations

On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations.  Starting within Novartis Technical Operations, this multiyear alliance aims to put real-time analytics in the hands of associates, empowering them to make better business decisions and increase efficiencies across manufacturing processes and supply chain.

…

/by

Amazon Web Services (AWS) Announces Strategic Collaboration with Novartis to Accelerate Digital Transformation of its Business Operations

On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations.  Starting within Novartis Technical Operations, this multiyear alliance aims to put real-time analytics in the hands of associates, empowering them to make better business decisions and increase efficiencies across manufacturing processes and supply chain.

…

/by

Behind the research driving our data at medical conferences

At the American Society of Hematology (ASH) Annual Meeting & Exposition and the San Antonio Breast Cancer Symposium (SABCS) in December, Novartis will present more than 180 abstracts. 

We have a rich history of research and development (R&D) in the areas of hematology and oncology. For decades, we have leveraged learnings from both successes and setbacks to broaden our understanding of unmet patient needs, and identify ways to help transform the standard of care for those with blood disorders and cancer. Some of these scientific insights, combined with the information and …

/by

Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms

  • With more than 140 abstracts, Novartis continues its leadership in hematology innovation
     
  • Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in patients with high-risk MDS and AML
     
  • Safety and efficacy data for Kymriah® (tisagenlecleucel)* in real-world setting compared to pivotal trials in relapsed/refractory ALL and DLBCL
     
  • Adakveo® (crizanlizumab) post-hoc analyses of hospitalization data from the SUSTAIN study and interim …
/by